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Abstract: The placenta is the principal organ regulating 
respiratory, nutritional, endocrine and metabolic functions 
on behalf of the developing fetus. Changes in gene expres-
sion patterns of placenta-specific genes may influence fetal 
growth. We profiled the expression of 17 genes related to 
placenta functioning in term placentas (n = 677) to identify 
genes differentially expressed across birth weight catego-
ries [small (SGA), appropriate (AGA) and large (LGA) for ges-
tational age]. ABCG2, CEBPB, CRH, GCM1, GPC3, INSL4, PGF 
and PLAC1 were inversely associated with LGA status, with 
odds ratios (ORs) and 95% confidence intervals (CI) ranging 
from GCM1 (OR = 0.44, 95% CI: 0.29, 0.70) to CRH (OR = 0.73, 
95% CI: 0.61, 0.88). NR3C1 was positively associated with 
LGA status (OR = 2.33, 95% CI: 1.43, 3.78). PLAC1 (OR = 0.66, 
95% CI: 0.47, 0.92) and ABCG2 (OR = 0.63, 95% CI: 0.44, 0.91) 
were additionally inversely associated with SGA status, and 
PGF was positively associated with SGA status (OR = 1.59, 
95% CI = 1.08, 2.35). General trends were confirmed in an 
independent cohort (n = 306). Given that aberrant fetal 
growth may have long-lasting effects, our results suggest 
the potential utility of placental gene expression profiles as 
potential early markers of disease onset later in life.
Keywords: Birth weight; gene expression, placenta.
Introduction
Abnormal fetal growth, both undergrowth and overgrowth, 
has been linked to adverse health outcomes later in life, 
including metabolic as well as cognitive and neurobehavio-
ral disorders [1–3]. The placenta is a transient organ situated 
at the maternal-fetal interface that regulates fetal growth 
and development by facilitating nutrient intake and waste 
removal, gas exchange, immune protection and neuroendo-
crine functions on behalf of the developing fetus [4]. Given 
its important role in overseeing fetal development, placental 
gene expression patterns likely influence fetal growth.
While several studies have reported associations 
between genes relevant to placental function and birth-
weight, a proxy of fetal growth, many of these studies, 
including our own [5], focus on the relevance of imprinted 
genes as placental regulators of fetal growth [5, 6]. Recent 
studies have also implicated the importance of a broad 
range of non-imprinted genes, including genes involved 
in processes critical to the appropriate development of 
the placenta, such as differentiation, invasion, migra-
tion and syncytialization, as well as genes that play a 
role in regulating maternal and fetal physiology, such as 
neuroendocrine hormones and receptors [7]. However, 
studies to date linking regulators of placental function to 
fetal growth have focused on a small subset of genes and 
were limited by small sample sizes. Additional studies 
have linked genes with known relevance to placental 
function to severe pregnancy complications, including 
preeclampsia [8]. Given the important role of these genes 
in regulating placental function, variability of these genes 
in uncomplicated pregnancies may also bear relevance on 
fetal growth. Hence, a more comprehensive assessment 
to explore genes relevant to a broader range of placental 
functions in relation to fetal growth is warranted.
We assembled a panel of 17 genes that were previ-
ously shown to play a critical role in placenta function. The 
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selection was based on the following criteria: (1) highly/
uniquely expressed in placental tissue; (2) demonstrated 
functional role in fetal development (ABCG2, CEBPB, CRH, 
CSHL1, GH2, INSL4, NR3C1, and PLAC8); or (3) demonstrated 
association with pregnancy complications (CSH1, EPAS1, 
GCM1, GPC3, HIF1A, NR3C2, PGF, PLAC1, and PLAC4). The 
selected genes and their relevance to placental function and 
birth outcomes are shown in Table  1. The objective of this 
study is to determine whether the expression levels of these 
“placenta regulatory genes” are associated with fetal growth.
Materials and methods
Study population
This study involves two independent birth cohorts. The first consisted 
of mother-infant pairs enrolled in the Rhode Island Child Health Study 
(RICHS) with available placental RNA (n = 684), as previously described 
[37]. Briefly, the study selectively recruited small for gestational age 
(SGA, lowest 10th percentile), large for gestational age (LGA, highest 10th 
percentile) and matched appropriate for gestation age (AGA) infants 
based on the 2013 Fenton growth chart from Women and Infants Hos-
pital of Rhode Island. Lifestyle/demographic characteristics and expo-
sure histories were obtained from structured chart reviews of medical 
records and interviewer-based questionnaires. All subjects provided 
written informed consent approved by the Institutional Review Boards 
at Women and Infants Hospital and Emory University.
As the RICHS population is predominantly Caucasian (78%) and 
oversampled for SGA and LGA infants, we conducted a replication 
study in the Stress in Pregnancy (SIP) study [38], an on-going urban 
birth cohort that is more ethnically diverse and has a birth weight distri-
bution comparable to general population. The current study includes 
mother-infant pairs recruited from prenatal clinics at the Icahn School 
of Medicine at Mount Sinai, New York Hospital of Queens and Queens 
College with available placental RNA. We restricted our analysis to sin-
gleton pregnancies with gestational age ≥37 and maternal age ≥18 to 
match exclusion criteria implemented in the RICHS cohort (n = 307).
Placenta collection and RNA extraction
Placental biopsies free of maternal decidua were excised from each 
of four quadrants midway between the cord insertion site and the 
placental rim within 2 h of delivery to optimize RNA integrity. The tis-
sues were subsequently snap-frozen in liquid nitrogen, homogenized 
with mortar and pestle, and stored at −80°C. RNA was extracted from 
RICHS placenta samples using the RNeasy mini kit (Qiagen, #74106) 
and from SIP samples using the Maxwell simplyRNA Tissue Kit (Pro-
mega, #AS1280), following the manufacturer’s protocol. Extracted 
RNA was quantified using a Nanodrop spectrophotometer (Thermo 
Fisher Scientific Inc., #ND-2000) and stored at −80°C until use.
Gene expression profiling
Placental RNA was profiled using a custom-designed code-set 
(nanoString Technologies, Seattle, WA, USA) as previously described 
[5]. Briefly, RNA was hybridized to reporter and capture probes, and 
purified target-dual probe complexes were aligned and immobilized 
Table 1: Panel of selected genes.
Gene symbol Function Birth outcome
ABCG2 Placental drug efflux transporter [9] Placental choriocarcinoma [10]
CEBPB Transcription factor that induces decidualization of stromal cells [11]
CRH Neuroendocrine hormone that likely plays an important role in gestational 
length and parturition [12]
Predictor of pre-term birth; fetal growth 
restriction [13]
CSH1 Vasodilator hormone [14] Altered expression in SGA and LGA infants 
[7, 13]
CSHL1 Placental growth hormone; regulation of maternal/fetal metabolism [15] Altered expression in SGA and LGA infants [7]
EPAS1 Placental angiogenic factor [16] Preeclampsia [17] 
GCM1 Trophoblast differentiation [18] Preeclampsia [19]
GH2 Growth hormone; regulation of maternal/fetal metabolism [20] Altered expression and levels in SGA infants 
[7]
GPC3 Trophoblast differentiation [21] Simpson-Golabi-Behmel fetal overgrowth 
syndrome [22]
HIF1A Angiogenesis [23] Preeclampsia [24]
INSL4 Trophoblast invasion and migration [25] Placenta accrete [26]
NR3C1 Glucocorticoid receptor [27] Infant neurobehavior [28]
Birth weight [29]
NR3C2 Mineralocorticoid receptor; decidualization of stromal cells [30]
PGF Placental angiogenic factor [31] Preeclampsia [32]
PLAC1 Trophoblast invasion and migration into maternal decidua [33] Preeclampsia [34]
PLAC4 Promotes syncytialization [35] Preeclampsia [35]
PLAC8 Embryo development and implantation [36]
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on imaging cartridges using an nCounter Prep Station II. Cartridges 
were scanned in an nCounter Digital Analyzer for code count detec-
tion. The nanoString Norm R package was used to normalize nCounter 
data. The raw code count data was normalized against the geometric 
mean of spike-in positive control probes and against the geometric 
mean of the housekeeping genes, GAPDH, RPL19, and RPLP0. The 
limit of detection (LOD) for each sample was set at 2 standard devia-
tions above the mean of the included negative control probes. For 
each sample, expression values that fell below the LOD were set to 
LOD/sqrt2. Seven samples in the RICHS data-set and one sample in 
the SIP dataset were removed due to poor quality control metrics, 
leaving a sample size of 677 and 306, respectively.
Statistical analysis
Genes differentially expressed across birth weight categories (SGA, 
AGA, LGA) were identified using the limma R package (FDR < 0.05). The 
identified differentially expressed genes were further evaluated using 
multinomial logistic regression models (nnet R package), with the out-
come modeled as SGA and LGA infants referenced against AGA infants 
in both the RICHS and SIP data-sets. In the SIP data-set, we additionally 
conducted generalized linear models (GLM) to assess the association 
between gene expression levels and Fenton growth percentile, modeled 
as a continuous variable. All regression models were adjusted for a pri-
ori determined covariates, including batch, infant ethnicity and mater-
nal age. Gender and gestational age were accounted for in the Fenton 
growth chart defined outcome variable. Additional covariates, including 
maternal pre-pregnancy body mass index (BMI), maternal insurance, 
and maternal education were not included in the final models as their 
effect size estimates were less than 10%. All data was analyzed using R 
version 3.2.3 [39].
Results
The demographic and clinical characteristics of the 
RICHS [5] and SIP study [38] populations have been pre-
viously described and are summarized in Table 2. Briefly, 
the RICHS study population is predominately Caucasian 
(78.2%), with SGA, AGA and LGA infants constituting 
approximately 20%, 56% and 24%, respectively. Male and 
female infants were equivalently represented. The gesta-
tional age spanned the term range of 37–41 weeks.
Compared to the RICHS cohort, the birth weight 
distribution of the SIP study more closely reflects the 
general population, with SGA and LGA infants constitut-
ing approximately 10% each of the study population [40]. 
Mothers enrolled in SIP tended to be younger (maternal 
age <21 = 17.3%) than RICHS participants (maternal age 
<21 = 6.0%) A greater proportion of late term pregnancies 
were observed among the SIP participants (gestational age 
>40  weeks = 24.5%) compared to the RICHS participants 
(gestational age >40  weeks = 7.4%). As the SIP study rep-
resents an urban, ethnically diverse cohort, a significantly 
greater proportion of SIP population are non-white (78.4%) 
compared to RICHS (21.4%). No differences in the gender 
distribution were observed between the two populations.
As shown in Figure 1, nine genes were differentially 
expressed between LGA and AGA infants; eight genes 
(ABCG2, CEBPB, CRH, GCM1, GPC3, INSL4, PLAC1, PGF) 
were downregulated in LGA infants, and NR3C1 was upreg-
ulated in LGA infants. Meanwhile, PGF was the only gene 
differentially expressed between SGA and AGA infants, 
with an upregulation observed among SGA infants in 
addition to the downregulation observed among LGA 
infants compared to AGA infants.
We further analyzed the association between the 
identified differentially expressed genes and fetal growth 
using multinomial logistic regression analysis, adjusting 
the models for plate batch, infant ethnicity, and mater-
nal age. As seen in Figure 2, compared to AGA status, a 
log2 unit increase in expression of eight genes (ABCG2, 
CEBPB, CRH, GCM1, GPC3, INSL4, PGF and PLAC1) was 
associated with a significant decrease in odds of LGA 
status, ranging from GCM1 (OR = 0.44, 95% CI: 0.29, 0.68) 
to CRH (OR = 0.73, 95% CI: 0.61, 0.88). A concomitant sig-
nificant increase in the odds of SGA status was observed 
with a log2 unit increase in PGF expression (OR = 1.59, 95% 
CI: 1.08, 2.35). In contrast, a log2 unit increase in NR3C1 










n  % n  %
Birth weight category           <0.01
 SGA   130  19.2  38  12.4 
 AGA   387  57.2  245  80.1 
 LGA   160  23.6  23  7.5 
Infant gender           0.44
 Male   332  49.0  159  52.0 
 Female   345  51.0  147  48.0 
Maternal age (year)           <0.01
 18–21   40  6.0  53  17.3 
 22–30   295  39.7  140  45.8 
  ≥ 31   342  54.3  69  22.5 
 Missing   0  0  44  14.4 
Infant race           <0.01
 White   515  76.1  26  8.5 
 Black   54  8.0  64  20.9 
 Hispanic/other   78  11.5  156  51.0 
 Asian   13  1.9  20  6.5 
 Missing   17  2.5  40  13.1 
Gestational age (week)           <0.01
  ≤ 38   132  19.5  68  22.2 
 39–40   494  73.1  163  53.3 
  > 40   51  7.4  75  24.5 
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expression was associated with increased odds of LGA 
status (OR = 2.33, 95% CI: 1.43, 3.78). For two genes, ABCG2 
and PLAC1, a log2 unit increase in expression was associ-
ated with lower odds of both LGA and SGA status.
Because the RICHS cohort was designed to study aber-
rant fetal growth, the study population was oversampled 
at both ends of fetal growth (SGA and LGA), resulting in a 
birthweight distribution that differs from the general pop-
ulation. To assess the robustness of our findings, we con-
ducted a replication study in the SIP cohort to determine 
whether associations observed in the RICHS also present 
in a study population with a more normal birth weight dis-
tribution and a more diverse ethnic composition.
In the SIP study, gene expression data was available for 
8 (ABCG2, CEBPB, EPAS, GCM1, NR3C1, GCM1, PGF, PLAC1, 
PLAC4) of the 17 assessed placenta regulatory genes in the 
RICHS study. As shown on Table 3, increased expression 
levels of CEBPG and GCM1 were significantly associated with 
decreased odds of LGA status, consistent with findings in the 
RICHS study. Consistent trends were also observed between 
NR3C1 expression and fetal growth in both cohorts, with a 
significant positive association between NR3C1 expression 
and LGA status in the RICHS cohort and a significant inverse 
association between NR3C1 expression and SGA status in 
the SIP cohort. In the SIP cohort, GCM1 and EPAS were addi-
tionally associated with increased odds of SGA status. Inter-
estingly, borderline significant positive associations were 
observed between ABCG2 and PLAC1 expression levels and 
SGA status, contrary to findings in the RICHS study, where 













Figure 2: Association between placental gene expression and birth 
weight categories in the RICHS cohort.
Odds ratios (OR) and 95% CI for SGA or LGA status referenced 
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Figure 1: Genes differentially expressed between aberrant and normal birth weight categories.
Genes differentially expressed between SGA/AGA and LGA/AGA birth weight categories (FDR < 0.05) are labeled in blue.
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Given the normal distribution in Fenton growth per-
centiles in the SIP cohort, we further explored the rela-
tionship between placental gene expression levels and 
fetal growth modeled as a continuous outcome using gen-
eralized linear models. Significant associations with fetal 
growth were observed for six of the eight assessed genes. 
Consistent with the findings of the multinomial models, 
NR3C1 was the only gene positively associated with fetal 
growth while among the genes inversely associated with 
fetal growth, GCM1 was among the genes with the largest 
negative effect size (Table 4).
Discussion
Findings from our study demonstrate that changes in the 
expression of several placenta-specific genes are associ-
ated with fetal growth. An inverse association between 
fetal growth and the expression levels of CEBPB, GCM1 
and PLAC1 and a positive association between fetal 
growth and NR3C1 expression was consistently observed 
across two independent study populations with different 
sociodemographic characteristics; these robust results 
implicate the relevance of these genes to fetal growth.
The three genes inversely associated with LGA status 
predominately function in processes related to placental 
differentiation processes (CEBPB, GCM1, and PLAC1). For 
example, CEBPB is a transcription factor that is involved 
in the induction of stromal decidualization [11] and both 
GCM1 [41, 42] and PLAC1 [33, 43] promote trophoblast syn-
cytialization and invasion. The observed inverse associa-
tion between the expression of these genes and fetal growth 
may reflect the increased activity of these genes in hasten-
ing placental maturation among growth-restricted infants.
The glucocorticoid receptor NR3C1 is a critical com-
ponent of the placental regulatory pathway that controls 
fetal exposure to glucocorticoids, including cortisol. 
Elevated glucocorticoid levels at term have been previ-
ously associated with fetal growth retardation [44]. More 
recently, increased cord blood NR3C1 methylation levels 
have been associated with both stress during pregnancy 
and decreased offspring birth weight, suggesting that 
this gene may act as a potential mediator linking mater-
nal stress during pregnancy with fetal growth [29]. Given 
an inverse relationship between methylation and gene 
expression, our findings of a positive association between 
NR3C1 expression and birth weight are consistent with the 
previous report of an inverse association between NR3C1 
methylation and birth weight.
While findings between the two cohorts were largely 
consistent with one another, contrary findings were 
observed for two genes, ABCG2 and PLAC1. For both genes, 
U-shaped associations were observed in the RICHS study, 
with significant inverse associations with both SGA and 
LGA status. In the SIP study, however, borderline posi-
tive associations with SGA status were observed for both 
genes. These differences may point to the sensitivity of our 
findings related to these genes to underlying differences 
Table 3: Associations between placental regulatory genes and fetal growth in RICHS and SIPa.
RICHS [OR (95% CI)] SIP [OR (95% CI)]
SGA LGA SGA LGA
ABCG2 0.63 (0.44, 0.91) 0.52 (0.37, 0.74) 1.43 (0.97, 2.12) 0.68 (0.40, 1.15)
CEBPB 1.20 (0.77, 1.88) 0.48 (0.33, 0.71) 1.36 (0.77, 2.40) 0.48 (0.23, 0.97)
EPAS 1.28 (0.66, 2.48) 0.56 (0.32, 1.00) 2.32 (1.01, 5.33) 0.59 (0.24, 1.46)
GCM1 1.20 (0.75, 1.91) 0.44 (0.29, 0.68) 1.78 (1.11, 2.87) 0.56 (0.34, 0.91)
NR3C1 0.69 (0.40, 1.20) 2.33 (1.43, 3.78) 0.29 (0.12, 0.73) 1.15 (0.34, 3.91)
PGF 1.59 (1.08, 2.35) 0.53 (0.38, 0.73) 1.19 (0.85, 1.66) 0.83 (0.56, 1.22)
PLAC1 0.66 (0.47, 0.92) 0.58 (0.43, 0.79) 1.26 (0.97, 1.64) 0.76 (0.56, 1.04)
PLAC4 0.82 (0.60, 1.13) 0.87 (0.64, 1.17) 1.12 (0.91, 1.38) 0.85 (0.69, 1.06)
aModels adjusted for infant race and maternal age. Significant associations with the outcome are indicated in bold.
Table 4: Generalized linear models assessing the association 
between placental regulatory gene expression and Fenton growth 
percentiles in the SIP cohorta.
Gene β 95% CI
ABCG2 −0.04 [ − 0.07, −0.01]
CEBPB −0.06 [ − 0.11, −0.02]
GCM1 −0.07 [ − 0.10, −0.03]
EPAS1 −0.07 [ − 0.13, −0.01]
NR3C1 0.12 [0.04, 0.20]
PGF −0.03 [ − 0.06, −0.01]
PLAC1 −0.03 [ − 0.05, 0.00]
PLAC4 −0.02 [ − 0.04, 0.00]
aModels adjusted for infant race and maternal age.
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in these populations. Additional studies are warranted 
to further evaluate contributing drivers in the associa-
tion between these genes and aberrant fetal growth. The 
observed discrepancy in our findings highlights the 
importance of replicating studies across multiple cohorts 
of varying characteristics to identify robust associations.
While several studies have suggested an association 
between fetal development and the expression of genes 
implicated to play placental-specific roles in develop-
ment, this study represents the most comprehensive pro-
filing of the expression of placental regulatory genes in 
healthy, term pregnancies. The large sample size and sam-
pling scheme based on fetal growth categories ensured 
sufficient power to detect meaningful risk factors for 
birth weight. Expression was profiled in the placenta, the 
principal regulator of fetal development and the organ in 
which the selected genes are almost uniquely expressed. 
Additionally, the inclusion of a replication study provides 
a means to assess the robustness of the presented findings.
However, certain limitations were also inherent to 
our study design. For example, the over-representation of 
infants at the extremes of the birth weight spectrum could 
limit the generalizability of the findings to the general 
population. We attempted to address this issue by includ-
ing a replication study with a more normal birth weight 
distribution. Also, we are unable to capture the dynamics 
in the expression of these genes throughout the in utero 
period and, therefore, are unable to identify potential crit-
ical windows of susceptibility. Finally, while we observe 
associations between placental markers and birth weight, 
we cannot infer the directionality of the associations 
due to the cross-sectional nature of the study. Hence, it 
is unclear whether the changes in expression reflect an 
adaptive or pathologic response to the processes under-
lying abnormal fetal growth. Additional longitudinal 
studies are warranted to evaluate whether the observed 
changes in placental gene expression have implications 
on health outcomes later in life.
In summary, we identified associations between fetal 
growth and the expression pattern of a panel of genes 
involved in placental regulatory processes. Given the 
implications of aberrant fetal growth on health effects 
throughout the lifespan, our findings suggest that placen-
tal regulatory gene expression profiles have the potential to 
be leveraged as early markers of disease onset later in life.
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